RU2020121222A - Агонисты fxr для лечения заболеваний печени - Google Patents
Агонисты fxr для лечения заболеваний печени Download PDFInfo
- Publication number
- RU2020121222A RU2020121222A RU2020121222A RU2020121222A RU2020121222A RU 2020121222 A RU2020121222 A RU 2020121222A RU 2020121222 A RU2020121222 A RU 2020121222A RU 2020121222 A RU2020121222 A RU 2020121222A RU 2020121222 A RU2020121222 A RU 2020121222A
- Authority
- RU
- Russia
- Prior art keywords
- dose
- alcoholic
- treatment
- tropifexor
- cholelithiasis
- Prior art date
Links
- 208000019423 liver disease Diseases 0.000 title claims 4
- 239000000556 agonist Substances 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 10
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 6
- VYLOOGHLKSNNEK-PIIMJCKOSA-N OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 Chemical compound OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 VYLOOGHLKSNNEK-PIIMJCKOSA-N 0.000 claims 4
- 201000001883 cholelithiasis Diseases 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229940070126 tropifexor Drugs 0.000 claims 4
- 210000000013 bile duct Anatomy 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102100038495 Bile acid receptor Human genes 0.000 claims 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims 2
- 206010061876 Obstruction Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593084P | 2017-11-30 | 2017-11-30 | |
| US62/593,084 | 2017-11-30 | ||
| PCT/IB2018/059383 WO2019106550A1 (en) | 2017-11-30 | 2018-11-28 | Fxr agonists for the treatment of liver diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020121222A true RU2020121222A (ru) | 2021-12-30 |
| RU2020121222A3 RU2020121222A3 (https=) | 2022-04-19 |
Family
ID=64959384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020121222A RU2020121222A (ru) | 2017-11-30 | 2018-11-28 | Агонисты fxr для лечения заболеваний печени |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210361638A1 (https=) |
| EP (1) | EP3716977A1 (https=) |
| JP (1) | JP2021504370A (https=) |
| KR (1) | KR20200094175A (https=) |
| CN (1) | CN111356458A (https=) |
| AU (1) | AU2018376904B2 (https=) |
| CA (1) | CA3081656A1 (https=) |
| IL (1) | IL274747A (https=) |
| MX (1) | MX2020005557A (https=) |
| RU (1) | RU2020121222A (https=) |
| TW (1) | TW201936189A (https=) |
| WO (1) | WO2019106550A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021014349A1 (en) * | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising fxr agonists |
| WO2021064575A1 (en) * | 2019-09-30 | 2021-04-08 | Novartis Ag | Treatment comprising the use of fxr agonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1734970T3 (pl) * | 2004-03-12 | 2015-05-29 | Intercept Pharmaceuticals Inc | Leczenie zwłóknienia z zastosowaniem ligandów FXR |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| ES2902404T3 (es) * | 2016-02-22 | 2022-03-28 | Novartis Ag | Métodos para utilizar agonistas de fxr. |
| ES2862194T3 (es) * | 2016-02-22 | 2021-10-07 | Novartis Ag | Métodos para usar agonistas del FXR |
| MX384205B (es) * | 2016-02-22 | 2025-03-14 | Novartis Ag | Metodos para usar agonistas de fxr. |
| AR114930A1 (es) * | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
-
2018
- 2018-11-28 EP EP18830302.8A patent/EP3716977A1/en not_active Withdrawn
- 2018-11-28 US US16/767,078 patent/US20210361638A1/en not_active Abandoned
- 2018-11-28 KR KR1020207017973A patent/KR20200094175A/ko not_active Ceased
- 2018-11-28 RU RU2020121222A patent/RU2020121222A/ru unknown
- 2018-11-28 WO PCT/IB2018/059383 patent/WO2019106550A1/en not_active Ceased
- 2018-11-28 US US16/202,637 patent/US20190161483A1/en not_active Abandoned
- 2018-11-28 MX MX2020005557A patent/MX2020005557A/es unknown
- 2018-11-28 AU AU2018376904A patent/AU2018376904B2/en not_active Ceased
- 2018-11-28 TW TW107142391A patent/TW201936189A/zh unknown
- 2018-11-28 CN CN201880074342.4A patent/CN111356458A/zh active Pending
- 2018-11-28 CA CA3081656A patent/CA3081656A1/en active Pending
- 2018-11-28 JP JP2020528867A patent/JP2021504370A/ja active Pending
-
2020
- 2020-05-18 IL IL274747A patent/IL274747A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190161483A1 (en) | 2019-05-30 |
| AU2018376904A1 (en) | 2020-05-21 |
| RU2020121222A3 (https=) | 2022-04-19 |
| TW201936189A (zh) | 2019-09-16 |
| JP2021504370A (ja) | 2021-02-15 |
| CN111356458A (zh) | 2020-06-30 |
| WO2019106550A1 (en) | 2019-06-06 |
| EP3716977A1 (en) | 2020-10-07 |
| MX2020005557A (es) | 2020-08-20 |
| KR20200094175A (ko) | 2020-08-06 |
| CA3081656A1 (en) | 2019-06-06 |
| US20210361638A1 (en) | 2021-11-25 |
| AU2018376904B2 (en) | 2021-07-22 |
| IL274747A (en) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018133298A (ru) | Способы применения агонистов fxr | |
| JP2018507914A5 (https=) | ||
| AU2019222911A1 (en) | Berberine salts, ursodeoxycholic salts and combinations, methods of prepration and application thereof | |
| JP6099609B2 (ja) | 肺炎症を低減するためのレボフロキサシンの吸入 | |
| JP2022180461A5 (https=) | ||
| RU2018133158A (ru) | Способы применения агонистов fxr | |
| JP2020073546A5 (https=) | ||
| WO2010121128A3 (en) | Compositions and methods for treating or inhibiting liver injury | |
| JP2018514534A5 (https=) | ||
| FI3735295T3 (fi) | Parannetut peptidilääkkeet nashin ja muiden sairauksien hoitoon | |
| BR112012015282A2 (pt) | composição farmacêutica de liberação controlada | |
| JP2015038135A5 (https=) | ||
| RU2018136872A (ru) | Композиции, содержащие 15-oh эпк, и способы их применения | |
| JP2017522264A5 (https=) | ||
| JP6762931B2 (ja) | 経鼻組成物と該経鼻組成物の使用方法の改善 | |
| JP2009530413A5 (https=) | ||
| JP7175897B2 (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| CN101959429A (zh) | 抗微生物肽系统的激动剂 | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2016530279A5 (https=) | ||
| JP2021532171A5 (https=) | ||
| JP6878596B2 (ja) | Ｆｘｒアゴニストの組合せ | |
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia |